Dimensional Fund Advisors LP Raises Stock Holdings in argenx SE (NASDAQ:ARGX)

Dimensional Fund Advisors LP grew its position in argenx SE (NASDAQ:ARGX) by 21.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 24,929 shares of the company’s stock after acquiring an additional 4,445 shares during the quarter. Dimensional Fund Advisors LP’s holdings in argenx were worth $15,332,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of ARGX. Stephens Inc. AR purchased a new stake in shares of argenx in the fourth quarter valued at about $310,000. Ritholtz Wealth Management raised its stake in argenx by 85.5% during the 4th quarter. Ritholtz Wealth Management now owns 898 shares of the company’s stock valued at $552,000 after acquiring an additional 414 shares during the last quarter. Jones Financial Companies Lllp lifted its position in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company’s stock worth $41,000 after acquiring an additional 61 shares during the period. Park Avenue Securities LLC lifted its position in argenx by 40.0% during the 4th quarter. Park Avenue Securities LLC now owns 1,695 shares of the company’s stock worth $1,042,000 after acquiring an additional 484 shares during the period. Finally, Atomi Financial Group Inc. purchased a new position in shares of argenx in the 4th quarter valued at approximately $339,000. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Wedbush reissued an “outperform” rating and issued a $715.00 price objective on shares of argenx in a research note on Friday, April 11th. Wells Fargo & Company raised their price objective on shares of argenx from $723.00 to $741.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Deutsche Bank Aktiengesellschaft upgraded argenx from a “sell” rating to a “hold” rating in a research report on Wednesday, March 12th. William Blair reissued an “outperform” rating on shares of argenx in a report on Friday, February 28th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $720.00 price objective on shares of argenx in a report on Tuesday, April 8th. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $699.28.

argenx Trading Down 8.5 %

NASDAQ:ARGX opened at $570.13 on Friday. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21. The firm has a market cap of $34.81 billion, a price-to-earnings ratio of -647.88 and a beta of 0.57. The company’s 50-day moving average is $597.71 and its two-hundred day moving average is $613.12.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, equities research analysts forecast that argenx SE will post 3.13 earnings per share for the current fiscal year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.